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Metabolic breakdown of valproate (VPA), carbamazepine (CBZ) and phenytoin (PHT) by the cytochrome
P450 pathway generates toxic drug intermediates and reactive oxygen species (ROS). This mechanism
has been suspected to play a role in the pathogenesis of secondary cerebral folate deﬁciency (CFD). Using
KB-cell cultures, highly expressing the folate receptor 1 (FOLR1), the effect of antiepileptic drugs (AEDs)
and reactive oxygen species (ROS) on the FOLR1 dependent 5-methyltetrahydrofolate (MTHF) uptake was
studied. MTHF uptake is time and concentration dependent and shows saturation kinetics. At physiolog-
ical MTHF concentrations the high-afﬁnity FOLR1 represents the predominant mechanism for cellular
incorporation, while at high MTHF concentrations other transport mechanisms participate in folate
uptake. Exposure to PHT for more than 8 h led to a higher MTHF uptake and decreased cell count,
whereas MTHF uptake remained unaltered by VPA and CBZ. However, exposure to superoxide and hydro-
gen peroxide radicals signiﬁcantly decreased cellular MTHF uptake. By speciﬁc elimination and downreg-
ulation of FOLR1 using phosphatidyl-inositol-speciﬁc phospholipase C (PIPLC) and siRNA silencing, it was
shown that ROS not only inhibited FOLR1 mediated MTHF uptake but also affected all other mechanisms
of membrane-mediated MTHF uptake. Generation of ROS with the use of AED might therefore provide an
additional explanation for the disturbed folate transfer across the blood–CSF barrier in patients with CFD.
 2010 Elsevier Inc. All rights reserved.Introduction
5-Methyltetrahydrofolate (MTHF) is the predominant form of
folate in plasma and cerebrospinal ﬂuid (CSF). MTHF and its other
reduced folates are involved in various one-carbon exchange reac-
tions like the de novo synthesis of purines and thymidylate. MTHF
is also co-factor of methionine synthase catalyzing the conversion
of homocysteine to methionine and is the precursor for the acti-
vated methyl-group donor S-adenosyl-methionine which acts as
an important co-factor used in more than 100 different methyl-
transfer reactions including methylation of DNA, proteins and
phospholipids [1].
Folates are required by all cell types. Folate transport across cell
membranes is facilitated by at least three different mechanisms:
folate receptors (FOLR1 and FOLR2) with high afﬁnity for MTHF,
the reduced folate carrier (RFC) having low afﬁnity for MTHF
and, by passive MTHF diffusion at extremely high extracellularll rights reserved.
Hospital, Division of Clinical
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u).concentrations [2]. The glycosyl phosphatidyl-inositol (GPI) mem-
brane-anchored folate receptors (FOLR1 and FOLR2) posses high
afﬁnity for folate at concentrations within the nanomolar range
and is therefore able to bind physiological levels of folate [3,4].
FOLR1 shows a higher afﬁnity for MTHF compared to FOLR2. The
FOLR proteins are crucial for the assimilation, distribution and
retention of food folates while intestinal absorption depends also
on intact function of the co-transporter called the proton-coupled
folate transporter (PCFT) [5,6]. FOLR proteins have been identiﬁed
in a soluble form (FOLR3) within extracellular ﬂuids or attached to
various cell membranes (including KB-cells) with a tissue-speciﬁc
distribution. FOLR1 is predominantly expressed by epithelial cells
whereas FOLR2 is expressed by mesenchymal cells.
Normal brain development and function depend on active
MTHF transport by membrane-attached FOLR protein localized at
the basolateral membrane surface of choroid epithelium. After
binding to FOLR proteins, plasma MTHF is incorporated into cho-
roid epithelial cells against a concentration gradient by FOLR-med-
iated endocytosis and is subsequently delivered to the CSF
compartment [7,8]. By using this active vectorial transport CSF fo-
late levels are 1.5–2 times higher compared to blood folate levels
[9–11].
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deﬁciency (CFD) with low MTHF in spinal ﬂuid (CSF) was charac-
terized in pediatric patients [12]. Following high dose folinic acid
supplementation the group of youngest patients, diagnosed and
treated before the age of 6 years, showed a favorable and some-
times dramatic response with marked neurological recovery and
cessation of seizures, whereas the group of older children beyond
the age of 6 years tended to show a more delayed response with
incomplete neurological recovery. However, treatment with folinic
acid was able to prevent further deterioration [12]. The various eti-
ologies explaining low spinal ﬂuid MTHF levels have not been com-
pletely identiﬁed. In some patients the cause of CFD could be
attributed to circulating serum auto-antibodies against the mem-
brane-attached FOLR1 of the choroid plexus epithelial cells, pre-
venting the passage of MTHF into the spinal ﬂuid compartment
[13]. In addition, genetic defects of the FOLR1 gene have been
found recently in patients where autoimmunity was excluded
[14,15]. In the latter patients CSF folates are undetectable, thus
much lower than in other forms. Further monogenic causes of
CFD include 5,10-methylene-tetrahydrofolate reductase (MTHFR)
deﬁciency [16], 3-phosphoglycerate dehydrogenase (PGDH) deﬁ-
ciency dihydropteridine reductase (DHPR) deﬁciency [17], as well
as with Rett syndrome [18], Aicardi–Goutières syndrome [19], Al-
pers disease [20], Kearns–Sayre syndrome [21] and hereditary fo-
late malabsorption [22]. Unfortunately, in a minority of patients
suffering from CFD the etiology could not be identiﬁed. Different
factors interfering with MTHF binding or with the process of FOLR1
mediated endocytosis of choroid plexus have been suggested [23].
One hypothesis is that the use of antiepileptic drugs (AED) in CFD
patients with epilepsy interferes with folate metabolism and trans-
port across the blood–CSF barrier.
This hypothesis is based on the observation that the use of AED
(valproate; VPA, carbamazepine; CBZ) during pregnancy increased
the risk of neural tube defects (NTD) and congenital malformations
in the offspring of women suffering from epilepsy [24,25]. Folic
acid supplementation before and during pregnancy markedly re-
duced the risk of neural tube defects [26]. This led to the hypoth-
esis that NTDs due to AED are developmental disorders
secondary to folate deﬁciency in utero. Unlike in phenytoin (PHT)
where impaired intestinal deconjugation of dietary folates [27] or
increased catabolism of folates result in low folates in plasma,
erythrocyte and CSF and thus provided an explanation for the
development of congenital malformations, the pathophysiological
mechanisms in VPA or CBZ are not well understood [28].
To investigate the potential inﬂuence of different AED and/or
ROS on cellular FOLR1 dependent folate uptake a cell culture model
with KB-cells was created. 14C labeled MTHF uptake was deter-
mined under different experimental conditions.Materials and methods
KB-cells (human nasopharyngeal epidermoid carcinoma cells)
and Minimum Essential Medium Eagle were obtained from the
American Type Culture Collection (ATCC), 14C-5MTHF (speciﬁc
activity of 58.0 Ci mol) from Amersham Biosciences, folic acid-free
medium and phosphate buffered saline (PBS) from GIBCO, Invitro-
gen-Cooperation. Trypsin–EDTA (0.5%/0.2%), fetal calf serum (FCS),
OpiMEM and penicillin/streptomycin (10,000 IU/ml/10,000 lg/ml)
were obtained from BioConcept’s AMIMED, Switzerland. Xanthine,
xanthineoxidase, valproic acid sodium salt, carbamazepine, 5,5-
diphenylhydantoine, folic acid and trypan-blue were purchased
from Sigma–Aldrich, monoclonal antibody to folate receptor 1
(Mov18) from Alexis Biochemicals, FITC-conjugated AffniPure
Anti-mouse IgG from Milan Analytica, La Roche, Coelenterazine
fromMolecular Probes, Inc. (Eugene, Oregon, USA) and Ultima Goldsolution for liquid scintillation counter from Perkin Elmer. For scin-
tillation count a Packard liquid Scintillation Counter 1900 CA and
for detection of oxidative radicals a Turner Luminometer TD 20/
20 were used.
14C-MTHF uptake
Cellular 14C-MTHF uptake experiments were performed accord-
ing to the following general procedure: KB-cells were cultured in
minimal essential medium, containing 10% FCS and 5000 IU peni-
cillin and streptomycin. Sub-cultivation was performed every 4–
5 days at a ratio 1:3. Twenty-four hours before each experiment
70–80% conﬂuent cell dishes (60.1 cm2) were incubated over
5 min with 0.15 M Sodium chloride solution (pH 3.5) to strip mem-
brane-bound folates. After washing with PBS, cells were divided in
equal shares in new cell culture dishes and incubated overnight in
folic acid-free medium, containing 10% FCS and 5000 U penicillin/
streptomycin. Prior to the experiment the medium was exchanged
and fresh folic acid-free medium was added (10 ml). Depending on
the particular experimental setting 14C-MTHF was added together
with PIPLC, unlabeled MTHF, ROS or different AED’s. After incuba-
tion cells were washed three times with PBS and harvested with
1:10 diluted trypsin. Viable cells were determined by trypan-blue
and counted. Dishes containing more than 1.5  106 cells were dis-
carded. Subsequently cells were lysed by three cycles of freezing
and thawing.
To assess the uptake of 14C-MTHF centrifugation was performed
(3 min at 1090 U/m Hettich Rotina 46) and the supernatant con-
taining the cytosolic 14C-MTHF fraction was separated, 7.5 ml Ulti-
ma Gold solution was added and radioactivity was counted. From
the resulting counts per minute the background counts, achieved
from one milliliter washing solution was subtracted. All experi-
ments were done as triplicates and were expressed as pmol
MTHF/106 cells.
Time- and concentration-dependent 14C-MTHF uptake
For the time-dependent uptake 10 nmol/L 14C-MTHF was added
and incubated over 0.5, 1, 1.5, 2, 4, 8, 12 h at 37 C and 5% CO2. To
investigate concentration-dependent uptake 14C-MTHF was added
to the extracellular medium at concentrations of 10, 25, 40, 50, 75
and 100 nmol/L and measured after a period of 2 h.
14C-MTHF uptake in presence of non-labeled MTHF and PIPLC
Cells were incubated over 2 h both with 10–100 nmol/L 14C-
MTHF and in a second experiment together with 1000-fold in-
creased concentrations (10–100 lmol/L) of non-labeled MTHF (gift
from EPROVA, Switzerland), solved in an aqueous solution contain-
ing 1:2000 diluted 0.05% ascorbic acid solution. Pre-incubation
with 1000 U phosphatidyl-inositol-speciﬁc phospholipase C (PIP-
LC) is known to cleave the FOLR1 from its GPI anchor. To investi-
gate the inﬂuence of PIPLC, cells were pre-incubated with 500 or
1000 IU PIPLC (approximately 40–50 mU/105 cells) during 1 h.
14C-MTHF was added and after another incubation over 2 h the
cells were harvested, their viability determined and counted while
radioactivity was measured from the cell supernatant.
Small interference RNA (siRNA) silencing of FOLR1
To evaluate the impact of the FOLR1 and to exclude unspeciﬁc
effects of PIPLC speciﬁc small interference RNA (siRNA) silencing
was performed. For gene transfection KB cells were plated equally
into 6 cm wells and grown overnight until they were 60–80% con-
ﬂuent. One hour before transfection growth medium was changed
to OpiMEM without antibiotics and fetal calf serum. SiRNA was
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technology) as recommended form the manufacturer’s protocol
(125 pmol/L pre-designed siRNA (Ambion, Inc., Woodward, USA)
in 250 ll OptiMEM and 2.5 ll Lipofectamine 2000). OptiMEM
was exchanged to folic acid-free MEM after 8–12 h. The result of
siRNA silencing was evaluated by Western blot and gene expres-
sion analysis.
FOLR1 gene expression
To analyze FOLR1 gene expression levels under siRNA inhibition
total RNA was extracted from cell lysate at different time points
after transfection (QIAamp, RNA blood mini kit). Total RNA concen-
tration was quantiﬁed and single stranded cDNA synthesized by
reverse transcription according protocol (Promega Corporation:
Reverse transcription reaction). Quantitative gene FOLR1 gene
expression was studied by TaqMan Gene expression assay: Prim-
ers and a probe speciﬁc for the FOLR1 receptor gene were obtained
as Gene Expression Assay from Applied Biosystems. The 25 ll reac-
tion mixture contained in addition 50 ng cDNA, 12.5 ll TaqMan
Universal PCR Master Mix (Applied Biosystems) and RNase-free
water. 18S was used as controls. The reaction mixture was trans-
ferred to a MicroAmp optical 96-well reaction plate, incubated at
95 C for 10 min and then run for 40 cycles at 95 C for 15 s and
60 C for 60 s on the Applied Biosystems GeneAmp 7700 sequence
Detection System. The PCR results were analyzed with the Gene-
Amp SDS software (Applied Biosystems).
FOLR1 protein expression and 14C-MTHF uptake during siRNA silencing
FOLR1 expression studies were done by Western blot. Cells
were planted as usual in a 10-cm Petri dish. Cells were washed
in ice-cold PBS and lysated with 400 ll lyses buffer (20 mM Tris,
100 mM NaCl, 1 mM EDTA, 0.2% Triton X-100 and Complete Pro-
tease inhibitor Cocktail (Roche). Nucleic fraction was separated by
centrifugation at 4000g for 15 min. Afterwards membranes were
prepared by centrifugation of protein lysates at 200,000g during
1 h. Supernatant (cytosolic fraction) was separated and pellet
resuspended in 50 ll membrane buffer (0.3 M sucrose, 25 mM
imidazole, 1 mM EDTA, Complete Protease inhibitor Cocktail
(Roche)). Samples were frozen at 20 C. Protein concentration
was determined directly before doing Western blot analysis (Bio-
Rad Protein Assay). For protein separation equal amount of cyto-
solic and membrane protein were loaded on NuPAGE 4–12%
Bis–Tris Gel with MES running buffer (Invitrogen). Result was con-
trolled with Commassie blue staining. During Western blotting gel
was transferred to a nitrocellulose transfer membrane (Protan
Schleicher & Schuell, Germany). The blotting was incubated with
primary antibody against FOLR1 (1:500, Mov18, mouse derived)
followed by incubation with peroxidase conjugated secondary
antibody (1:5000 goat anti-mouse IgG labeled dilution, Sigma–Al-
drich). The speciﬁc protein was detected using an ECL Western blot
Detection Kit (Amersham bioscience). 14C-MTHF uptake to trans-
fected cells was measured as described above at 48, 72, 96, 120
and 144 h.
Uptake after exposure to oxygen radicals (ROS)
To analyze the inﬂuence of oxygen radicals, incubation with
14C-MTHF was performed in 10 ml Hanks balanced salt solution
(HBSS) containing 25 mg bovine serum albumin (Fluka, Switzer-
land) 100 lg transferrin and 20 lg insulin. Three millimolar xan-
thine and 0.2 U/L xanthine-oxidase were added. Xanthine is
metabolized by xanthine-oxidase to uric acid generating the pro-
duction of superoxide anions and hydrogen peroxide. Previous
tests had shown that this mixture is able to produce these ROS over60 min, without obvious harm to the cells. Before and 1 h after
adding 10 nmol/L or 50 nmol/L 14C-MTHF the amount of produced
reactive oxygen species was measured by Luminometer counting
after addition of 10 ll Coelenterazine. To exclude the possible oxi-
dation of the added 14C-MTHF itself by these free radicals, in a sec-
ond experiment cells were exposed to oxygen radicals before
adding 14C-MTHF. Only after conﬁrmation of the disappearance
of oxygen radicals, 14C-MTHF was added.14C-MTHF uptake after exposure to oxygen radicals (ROS) in presence
of PIPLC and during siRNA silencing
To asses if the inﬂuence of oxygen radicals on 14C-MTHF trans-
port is FOLR1 dependent, cells were pre-incubated with 1000 IU
PIPLC as described above and afterwards exposed to xanthine
and xanthine-oxidase as described before. Intracellular 14C-MTHF
was determined. In a second step 14C-MTHF uptake in siRNA trans-
fected cells after exposure to oxygen radicals was analyzed. Un-
treated cells and cells 72 h after siRNA transfection cells were
exposed to xanthine and xanthine-oxidase as described before.
14C-MTHF uptake in both cell types was measured. To conﬁrm that
changes of intracellular 14C-MTHF concentration were due to oxi-
dations stress, in a third experiment ascorbic acid at 30 lM was
added to neutralize reactive oxygen species. Previous experiments
had shown that ascorbic acid at this concentration has no side ef-
fect regarding cellular 14C-MTHF uptake or viability.Uptake in presence of valproic acid, carbamazepine or phenytoin
14C-MTHF (10 nmol/L) was added together with either physio-
logical concentrations of 1000 lmol/L valproic acid, 40 lmol/L car-
bamazepine (physiological concentrations) or 5–40 lg/ml
phenytoin. VPA was dissolved in water, CBZ and phenytoin was
solved in 1:10 dimethyl sulfoxide (DMSO, Sigma–Aldrich)/water
solution. Uptake and oxygen radicals were determined at time
points 1, 2, 4, 8, 12 and 24 h.FACS analysis
Cells were incubated during 1 h with ROS or 250, 500 and
1000 U PIPLC, as well as with physiological concentrations of
VPA, CBZ and phenytoin. Cells were solved from the plate by Ver-
sene solution (GIBCO, Invitrogen-Cooperation) to protect the mem-
brane-bound receptor. Cells were washed and resuspended in ice-
cold 2% FCS in PBS (washing solution). Anti-FOLR1 antibodies
(MoV18 1:100, derived from mouse) were added and incubated
during 45 min. After washing cells three times with washing solu-
tion secondary antibody (goat anti-mouse IgG, Fluorescein Isotho-
cyanate (FITC) conjugated, 1:200) for 45 min. After three washing
cycles ﬂuorescence was analyzed with ﬂow cytometry (FACS Cali-
bur BD Biosciences) and CellQuest Software (BD Biosciences).Results
14C-MTHF uptake characteristics
Kinetics of 14C-MTHF uptake by KB-cells was found to be both
concentration- and time-dependent. At constant extracellular
14C-MTHF concentrations of 10 nmol/L, a time-dependent satura-
tion plateau was reached after 120 min (Fig. 1a). At extracellular
14C-MTHF concentrations between 0 and 100 nmol/L, 14C-MTHF
uptake after 2 h incubation increased linearly between 0 and
50 nmol/L and showed saturation kinetics at concentrations from
75 to 100 nmol/L (Fig. 1b).
Fig. 1. (a) Concentration-dependent uptake of MTHF after incubation with
increasing 5MTHF concentration during 2 h. (b) Time-dependent uptake of 10 nM
5MTHF.
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port system operating at low extracellular concentrations, which
could be demonstrated by pre-incubation of KB-cells with 1000 U
PIPLC, known to cleave the FOLR1 from its GPI anchor (Fig. 2). Nearly
complete inhibition of uptake for PIPLC pre-incubated cells was no-
ticed at 10 nmol/L 14C-MTHF (96% inhibition = 0.03 pmol/106 cells
versus 0.71 pmol/106 cells). However, at progressively higher extra-
cellular 14C-MTHF concentrations PIPLC induced inhibition became
less effective (40 nmol/L = 72% inhibition (0.43 pmol/106 cells ver-
sus 1.51 pmol/106 cells) and 27% inhibition at 100 nmol/L
(1.43 pmol/106 cells versus 1.95 pmol/106 cells)). Thus, in order to
obtain a speciﬁc model focusing on FOLR1 mediated 14C-MTHF up-
take, experimentswere performed at an extracellular concentration
of 10 nmol/L 14C-MTHF (physiological concentration in humans).
To prove that PIPLC speciﬁcally decreases FOLR1 on KB cells,
ﬂow-cytometric analysis with monoclonal antibodies to FOLR1Fig. 2. Decreased intracellular 5MTHF after incubation with increasing MTHF
concentration for 2 h (d–d) in comparison with incubation in presence of 1000 mU
(h–h) phosphatidyl-inositol-speciﬁc phospholipase C and in presence of 1000-fold
concentration non-labeled 5MTHF (N–N) (minus background CPM, triplicates).was performed after pre-incubation with different concentrations
of PIPLC. Increasing PIPLC concentrations ranging from 250, 500
to 1000 mU resulted in a continuous loss of the percentage of cells
with positive monoclonal antibody binding against FOLR1
(Table 1).
To rule out non-speciﬁc effects of PIPLC on cellular folate trans-
port speciﬁc FOLR1 silencing was performed with small interfer-
ence RNA (siRNA). The level of messenger RNA of FOLR1 showed
a time dependent decrease. Already after 24 h FOLR1 gene expres-
sion was reduced to 20% of controls and at 48 h it reached its min-
imal percentage of 10% (Fig. 3a). Subsequently, it increased again to
reach normal values at 168 h after transfection. Protein expression
followed similar kinetics, but compared to the mRNA expression
downregulation of FOLR1 protein was delayed (Fig. 3b). It showed
a more moderate decrease, reached the minimal value of around
16% at 96 h and was at 144 h still at 40% of untreated controls.
14C-MTHF uptake by KB-cells after siRNA silencing was also time
dependent. At 48 h nearly a normal uptake was observed, followed
by continuous decrease to around 40% of control level after 120 h
(Fig. 3c).
14C-MTHF uptake after exposure to ROS
To evaluate 14C-MTHF uptake after exposure to reactive oxygen
radicals (ROS), the superoxide radical and hydrogen peroxide were
produced enzymatically. ROS signiﬁcantly reduced 14C-MTHF up-
take by KB-cells (Fig. 4) to an equal extent both at low concentra-
tions of 10 nmol/L (45%, 0.51 pmol/106 cells versus 0.28 pmol/106
cells; p = 0.014) and at higher extracellular concentrations of
50 nmol/L MTHF (44%, 1.59 pmol/106 cells versus 0.89 pmol/106
cells; p = 0.002). It should be stressed that the exposure to ROS
did not have any impact on cell count, viability or the binding of
monoclonal antibodies (Mov18) against FOLR1 as determined by
FACS analysis. To exclude the possibility of 14C-MTHF degradation
itself by these oxygen radicals, 14C-MTHF was added to the cell
medium after oxygen radicals had become undetectable.
To access whether loss of FOLR1 protein function is responsible
for the decreased uptake under exposure to ROS an experiment
using of 50 nmol/L extracellular 14C-MTHF concentration was per-
formed. Firstly, the FOLR1 was removed by PIPLC pre-incubation,
leading up to 76% reduction of expressed FOLR1 (see FACS analy-
sis). As consequence intracellular 14C-MTHF uptake was reduced
to 51% of control value (1.495 pmol/106 cells versus 0.73 pmol/
106 cells). Additional incubation of PIPLC pre-treated cells with
ROS resulted again in up to 90% decreased uptake, showing that
FOLR1 contributes only partially to the loss of 14C-MTHF uptake
after ROS exposure (Fig. 5). These ﬁndings could be conﬁrmed
and secondary effects of PIPLC could be excluded by 14C-MTHF up-
take studies in siRNA transfected cells. 14C-MTHF uptake was re-
duced to 50% in siRNA treated cells (see above). Under the
inﬂuence of ROS the uptake was further reduced both in the siRNA
treated group as well as in the control group (Fig. 6). Interestingly,
percent 14C-MTHF uptake between controls and FOLR1 silenced
cells remained the same, indicating again, that uptake reduction
was not due to speciﬁc loss of FOLR1 protein function. By addingTable 1
PIPLC decreases concentration-dependent binding of monoclonal anti-FOLR1 anti-
body (for details see ‘Materials and methods’).




Controls Anti-FOLR1 (Mov18) Goat anti-mouse IgG – 100
PIPLC 250 Anti-FOLR1 (Mov18) Goat anti-mouse IgG 250 60
PIPLC 500 Anti-FOLR1 (Mov18) Goat anti-mouse IgG 500 33
PIPLC 1000 Anti-FOLR1 (Mov18) Goat anti-mouse IgG 1000 24
Fig. 3. Downregulation of FOLR1 by siRNA interference technique. (a) Gene
expression is downregulated already after 24 h to 20% of control level. Expression
level stays on this level until 96 h and increases again after 120 h (Taqman analysis,
siRNA transfected cells versus controls, %). (b) FOLR1 expression level is also
downregulated. Compared to gene expression, protein expression is delayed and
reaches maximum downregulation after 96 h. (Western blot analysis, siRNA
transfected cells versus controls, %). (c) MTHF uptake decreases after 48 h
continuously to minimal level of 40% of controls after 120 h.
Fig. 4. ROS exposure leads to signiﬁcantly decreased 14C-MTHF uptake in balanced
salt solution (HBSS) containing bovine serum albumin, transferrin and insulin (1 h
incubation).
Fig. 5. PIPLC decreases MTHF uptake and coexposure with ROS and PIPLC leads to
an additional decrease, indicating an FOLR1 unrelated effect of ROS on 5MTHF
uptake 1 h incubation.
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ginal state, it was conﬁrmed that the reduced 14C-MTHF uptake
was caused by oxidative stress (data not shown).
14C-MTHF uptake in presence of valproic acid (VPA), carbamazepine
(CBZ) and phenytoin (PHT)
14C-MTHF uptake in the presence of therapeutic concentration
of VPA, CBZ and PHT was measured. No signiﬁcant difference with
respect to intracellular 14C-MTHF uptake or cell counts was noted
between the experiments performed with or without VPA or CBZ
(data not shown). In contrast exposure to 20 lg/ml PHT led to an
increased 14C-MTHF uptake after 8, 12 and 24 h (120%, 132% and
176%, respectively; Fig. 7a). Simultaneously, the cell count was re-
duced by 79% after 12 and by 70% after 24 h exposure to PHT
(Fig. 7b).The observed effect of PHT on the cell count was depend-
ing on the concentration of added PHT (data not shown). FACS
analysis did not reveal any direct effect of AED on anti-FOLR1 anti-
bodies binding to KB-cells.Discussion
The etiology of cerebral folate deﬁciency (CFD) is only partly
understood. Apart from high titers of auto-antibodies and genetic
defects of the FOLR1 gene further unknown factors interfering with
MTHF binding or with the process of FOLR1 mediated endocytosis
have to be discussed. [23]. Antiepileptic treatment during earlyFig. 6. Uptake of MTHF in presence of ROS in siRNA transfected and untreated cells:
MTHF uptake is reduced in siRNA treated cells. ROS lead to further reduction of 14C-
MTHF uptake both in the siRNA treated group as well as in the control group. After
addition of vitamin C 5MTHF uptake is restored to the normal level again. K:
control.
Fig. 7. (a) Phenytoin leads to signiﬁcant higher intracellular MTHF after incubation
of 12 h White boxes control group (all results minus background CPM). (b) Similar
exposure to phenytoin results in a decreased cell count after incubation longer than
12 h. (20 lg/ml phenytoin (dashed line, d– –d) in comparison with control group
(continuous line, j–j)).
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nism explaining development of a NTD during use of AED in preg-
nancy remains not entirely clear it appears to be linked to in utero
folate deﬁciency during embryonic neural tube closure. A compa-
rable mechanism can be discussed in CFD patients with epilepsy.
Here a direct impact of AED or of intermediary drug metabolites
or of reactive oxygen species generated during their metabolic
breakdown is possible. To study the effect of AED and ROS on folate
homoeostasis, intracellular uptake and transport across intestinal,
placental and blood–brain barriers we used an in vitro model of
KB-cells highly expressing the FOLR1.
First, 14C-MTHF cellular incorporation under normal conditions
was studied. Initial kinetics studies conﬁrmed earlier data showing
that at physiological serum concentrations (10–30 nmol/L) the 14C-
MTHF uptake is time- and concentration dependent with satura-
tion kinetics [29]. For each individual concentration a saturation
plateau was reached after 2 h and a plateau of maximum uptake
occurred for concentrations exceeding 75 nmol/L 14C-MTHF. Com-
parison of MTHF uptake with or without PIPLC proved that at low
physiologic extracellular concentrations, MTHF uptake is only
mediated by the FOLR1. To focus our investigations on the FOLR1,
our ﬁrst experiments were performed at the 10 nmol/L 14C-MTHF
concentration.
Exposure to VPA and CBZ did not alter MTHF uptake signiﬁ-
cantly whereas exposure to PHT resulted in direct inhibition of cell
growth and increased folate uptake. An increasedMTHF uptake un-
der the inﬂuence of PHT might explain the decreased serum folate
levels in patients receiving PHT treatment [30] but is not concor-
dant with the ﬁndings where PHT inhibits the uptake of folic acid
into isolated chick intestinal epithelial cells. The latter results are
likely to be explained by a direct effect on intestinal folic acid up-take mechanisms [31]. The reduced cell count is due to cytotoxicity
by PHT, already observed in various cell culture models [32–34].
The effect of PHT on folate uptake by different tissues still needs
further clariﬁcation, while earlier ﬁndings suggesting enhanced fo-
late catabolism by PHT need to be considered as well. Nevertheless,
folic acid supplementation should be an essential part of preven-
tive pregnancy care particularly among women suffering from
epilepsy.
However, during degradation of the other antiepileptic drugs
VPA and CBZ by the cytochrome P450 system, ROS are generated.
Our studies showed decreased 14C-MTHF uptake after exposure
to the in vitro generated ROS superoxide anions and hydrogen per-
oxide. To investigate the role of FOLR1 with respect to the reduced
folate uptake after ROS exposure, ﬁrst the receptor was removed
by pre-incubation of KB-cells with PIPLC. Under exposure to ROS
was still a signiﬁcant decreased uptake notable. In a second more
speciﬁc step FOLR1 was eliminated by siRNA silencing which con-
ﬁrmed the results. Therefore, the inhibition of 14C-MTHF uptake
cannot only be attributed to the interference of ROS with the
FOLR1. ROS are believed to lead to a more general functional loss
of all membrane-coupled folate uptake mechanisms including also
the RFC or other unidentiﬁed folate transporters. The radical scav-
enger vitamin C is able to alleviate the inhibitory effect of ROS on
cellular folate incorporation.
Our data might suggest alternative mechanisms for patients
with the CFD syndrome, in whom genetic FOLR1 abnormalities or
FOLR1 autoimmunity have been excluded. CFD is a newly identi-
ﬁed clinical syndrome with post-natal onset of irritability and
insomnia, followed by head growth deceleration, hypotonia and
ataxia, psychomotor retardation, spastic paraplegia, and in one-
third of patients epilepsy and dyskinesia [12]. The only detectable
biochemical abnormality is low MTHF in spinal ﬂuid, suggesting a
disorder of folate transport across the blood–CSF barrier. In the
majority of CFD patients, circulating FOLR1 auto-antibodies of
the blocking type have been identiﬁed in serum and have been sus-
pected to prevent the binding of MTHF to the membrane-attached
FOLR1 of choroid plexus [13]. Recently, in patients without FOLR1
autoimmunity a genetic defect of the FOLR1 gene has been found
[14,15]. Unfortunately, in a number of patients the cause remains
unknown, while one-third of these patients suffer from epilepsy
and receive AED. In the latter patients the generation of ROS with
or without the use of AED, might provide an additional explanation
being at the origin of disturbed folate transfer across the blood–CSF
barrier or aggravating brain folate deﬁciency.Acknowledgments
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